# A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494

> **NCT01741493** · PHASE1 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 67 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** ABT-494
- **DRUG:** Placebo
- **DRUG:** Tofacitinib

## Key facts

- **NCT ID:** NCT01741493
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2017-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01741493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01741493, "A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01741493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*